|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin6. 65:5–29. 2015. View Article : Google Scholar
|
|
2
|
Smith HO, Arias-Pulido H, Kuo DY, Howard
T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE and
Prossnitz ER: GPR30 predicts poor survival for ovarian cancer.
Gynecol Oncol. 114:465–471. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li C, Liu VW, Chan DW, Yao KM and Ngan HY:
LY294002 and metformin cooperatively enhance the inhibition of
growth and the induction of apoptosis of ovarian cancer cells. Int
J Gynecol Cancer. 22:15–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Correia S, Carvalho C, Santos MS, Proença
T, Nunes E, Duarte AI, Monteiro P, Seiça R, Oliveira CR and Moreira
PI: Metformin protects the brain against the oxidative imbalance
promoted by type 2 diabetes. Med Chem. 4:358–364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kourelis TV and Siegel RD: Metformin and
cancer: New applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gonzalez-Angulo AM and Meric-Bernstam F:
Metformin: A therapeutic opportunity in breast cancer. Clin Cancer
Res. 16:1695–1700. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Foretz M, Hébrard S, Leclerc J,
Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and
Viollet B: Metformin inhibits hepatic gluconeogenesis in mice
independently of the LKB1/AMPK pathway via a decrease in hepatic
energy state. J Clin Invest. 120:2355–2369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang YK, Kang WK, Shin DB, Chen J, Xiong
J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, et al:
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as
first-line therapy in patients with advanced gastric cancer: A
randomised phase III noninferiority trial. Ann Oncol. 20:666–673.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lorch JH, Goloubeva O, Haddad RI, Cullen
K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE and Posner
MR: TAX 324 Study Group: Induction chemotherapy with cisplatin and
fluorouracil alone or in combination with docetaxel in locally
advanced squamous-cell cancer of the head and neck: Long-term
results of the TAX 324 randomised phase 3 trial. Lancet Oncol.
12:153–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaina B: DNA damage-triggered apoptosis:
Critical role of DNA repair, double-strand breaks, cell
proliferation and signaling. Biochem Pharmacol. 66:1547–1554. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang J, Jung HH, Yang JY, Lee S, Choi J,
Im GJ and Chae SW: Protective effect of metformin against
cisplatin-induced ototoxicity in an auditory cell line. J Assoc Res
Otolaryngol. 15:149–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang YH, Wang Y, Yusufali AH, Ashby F,
Zhang D, Yin ZF, Aslanidi GV, Srivastava A, Ling CQ and Ling C:
Cytotoxic genes from traditional Chinese medicine inhibit tumor
growth both in vitro and in vivo. J Integr Med. 12:483–494. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yeh JJ, Routh ED, Rubinas T, Peacock J,
Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO and Der CJ:
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for
MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther.
8:834–843. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sirianni R, Chimento A, De Luca A,
Casaburi I, Rizza P, Onofrio A, Lacopetta D, Puoci F, Andò S,
Maggiolini M and Pezzi V: Oleuropein and hydroxytyrosol inhibit
MCF-7 breast cancer cell proliferation interfering with ERK1/2
activation. Mol Nutr Food Res. 54:833–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Albrecht DS, Clubbs EA, Ferruzzi M and
Bomser JA: Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate
cancer cell proliferation via MEK-independent ERK1/2 activation.
Chem Biol Interact. 171:89–95. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Steinmetz R, Wagoner HA, Zeng P, Hammond
JR, Hannon TS, Meyers JL and Pescovitz OH: Mechanisms regulating
the constitutive activation of the extracellular signal-regulated
kinase (ERK) signaling pathway in ovarian cancer and the effect of
ribonucleic acid interference for ERK1/2 on cancer cell
proliferation. Mol Endocrinol. 18:2570–2582. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan BK, Adya R, Chen J, Farhatullah S,
Heutling D, Mitchell D, Lehnert H and Randeva HS: Metformin
decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by
increasing the antiangiogenic thrombospondin-1. Cardiovasc Res.
83:566–574. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Janjetovic K, Vucicevic L, Misirkic M,
Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S,
Bumbasirevic V, Trajkovic V and Harhaji-Trajkovic L: Metformin
reduces cisplatin-mediated apoptotic death of cancer cells through
AMPK-independent activation of Akt. Eur J Pharmacol. 651:41–50.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei SQ, Sui LH, Zheng JH, Zhang GM and Kao
YL: Role of ERK1/2 kinase in cisplatin-induced apoptosis in human
ovarian carcinoma cells. Chin Med Sci J. 19:125–129.
2004.PubMed/NCBI
|
|
25
|
Kim EH, Na HK and Surh YJ: Upregulation of
VEGF by 15-deoxy-Delta12,14-prostaglandin J2 via heme oxygenase-1
and ERK1/2 signaling in MCF-7 cells. Ann NY Acad Sci. 1090:375–384.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elia EM, Quintana R, Carrere C, Bazzano
MV, Rey-Valzacchi G, Paz DA and Pustovrh MC: Metformin decreases
the incidence of ovarian hyperstimulation syndrome: An experimental
study. J Ovarian Res. 6:622013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Feng P, Zhang ZL, Zhang ZH, Zhang XL,
Xiang F, Tang JH and Xiang BL: Effect of endostar combined with
cisplatin on expression of VEGF and Sema3A of lewis lung cancer
rats. Asian Pac J Trop Med. 6:57–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boucher MJ, Morisset J, Vachon PH, Reed
JC, Lainé J and Rivard N: MEK/ERK signaling pathway regulates the
expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of
human pancreatic cancer cells. J Cell Biochem. 79:355–369. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yasmeen A, Beauchamp MC, Piura E, Segal E,
Pollak M and Gotlieb WH: Induction of apoptosis by metformin in
epithelial ovarian cancer: Involvement of the Bcl-2 family
proteins. Gynecol Oncol. 121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lesan V, Ghaffari SH, Salaramoli J,
Heidari M, Rostami M, Alimoghaddam K and Ghavamzadeh A: Evaluation
of antagonistic effects of metformin with Cisplatin in gastric
cancer cells. Int J Hematol Oncol Stem Cell Res. 8:12–19.
2014.PubMed/NCBI
|
